The safety profiles of avacopan on microscopic polyangiitis and granulomatosis with polyangiitis: a real-world pharmacovigilance analysis
BackgroundAvacopan is an oral selective C5a receptor inhibitor. It received FDA approval in October 2021 for use with standard glucocorticoid therapy to treat antineutrophil cytoplasmic antibody-associated vasculitis. However, there are limitations to understanding adverse events (AEs) in clinical p...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2025-10-01
|
| シリーズ: | Frontiers in Immunology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1654735/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|